title: Increased immunity and BRAF inhibition: Yet another argument for combination therapy?
authors.affiliation: The Departments of Tumor Biology and Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, United States. Electronic address: keiran.smalley@moffitt.org.
authors.forename: Keiran S M
authors.initials: KSM
authors.lastname: Smalley
mesh_terms: D000818:Animals; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects* / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D007211:Indoles / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage; D000077484:Vemurafenib
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf